N/A N=104

Retrospective Analysis of Outcomes With a Pharmacogenomic Algorithm

Depression · Anxiety

Bottom Line

View on ClinicalTrials.gov: NCT01632267 ↗

Enrolled (actual)

104

Serious AEs

0.0%

Results posted

Mar 2013

Primary outcome: Primary: Number of Outpatient Visits — 13 units on a scale

Study Design & Population

Study type: Observational
Phase: N/A
Interventions: —
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Assurex Health Inc.
Primary completion: Apr 2011

Outcome Measures

Outcome	Result	p-value
PRIMARY Number of Outpatient Visits	13	—
SECONDARY Number of Medical Absence Days	—	—
SECONDARY Number of Disability Claims	—	—

Summary

Antidepressants are among the most widely prescribed medications, yet only 35-45% of patients achieve remission following an initial antidepressant trial. The financial burden of treatment failures in direct treatment costs, disability, decreased productivity, and missed work may in part derive from a mismatch between optimal, and actual, medications prescribed. The present one year retrospective study seeks to evaluate the indirect and direct healthcare costs for 96 patients with a DSM-IV-TR depressive or anxiety disorder, in relation to an interpretive reporting system designed to predict antidepressant responses based on DNA variations in cytochrome P450 genes (CYP2D6, CYP2C19, CYP1A2), the serotonin transporter gene (SLC6A4), and the serotonin 2A receptor (5HTR2A) genes.

Eligibility Criteria

Inclusion Criteria

Major Depressive Disorder
Dysthymic Disorder
Depressive Disorder NOS
Obsessive Compulsive Disorder (OCD)
Generalized Anxiety Disorder
Panic Disorder
Anxiety Disorder NOS
Post-Traumatic Stress Disorder (PTSD)
Social Phobia

Exclusion Criteria

Bipolar Disorder
Schizophrenia
Schizoaffective Disorder
Previous pharmacogenomic testing

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01632267). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.